Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (C...
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkins...
L-dopa remains the mainstay treatment for Parkinson’s disease (PD), although in later stages, treatm...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
The nigrostriatal dopamine (DA) system has an essential role in the selection and control of movemen...
L-dopa-induced dyskinesia (LID) is the most frequent motor complication associated with chronic L-do...
L-dopa-induced dyskinesia (LID) is the most frequent motor complication associated with chronic L-do...
The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment...
L-dopa remains the mainstay treatment for Parkinson’s disease (PD), although in later stages, treatm...
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkins...
L-dopa remains the mainstay treatment for Parkinson’s disease (PD), although in later stages, treatm...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) the...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
The nigrostriatal dopamine (DA) system has an essential role in the selection and control of movemen...
L-dopa-induced dyskinesia (LID) is the most frequent motor complication associated with chronic L-do...
L-dopa-induced dyskinesia (LID) is the most frequent motor complication associated with chronic L-do...
The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment...
L-dopa remains the mainstay treatment for Parkinson’s disease (PD), although in later stages, treatm...
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkins...
L-dopa remains the mainstay treatment for Parkinson’s disease (PD), although in later stages, treatm...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...